GE HealthCare Technologies (NASDAQ:GEHC) Raised to Buy at Wall Street Zen

GE HealthCare Technologies (NASDAQ:GEHC) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently issued reports on the company. BMO Capital Markets started coverage on GE HealthCare Technologies in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $70.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating on shares of GE HealthCare Technologies in a research note on Thursday, July 30th. Weiss Ratings raised GE HealthCare Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, October 6th. UBS Group boosted their target price on shares of GE HealthCare Technologies from $67.00 to $73.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. Finally, Citigroup increased their price target on shares of GE HealthCare Technologies from $71.00 to $79.00 and gave the company a “neutral” rating in a research note on Thursday. Twelve equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $80.57.

GE HealthCare Technologies Stock Performance

Shares of GEHC stock opened at $76.57 on Friday. GE HealthCare Technologies has a 12-month low of $58.75 and a 12-month high of $89.77. The company has a quick ratio of 1.01, a current ratio of 1.30 and a debt-to-equity ratio of 0.86. The firm has a market cap of $34.62 billion, a P/E ratio of 16.15, a price-to-earnings-growth ratio of 1.93 and a beta of 0.64. The business has a 50-day moving average price of $68.45 and a two-hundred day moving average price of $70.06.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Wednesday, October 28th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.14. The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.35 billion. GE HealthCare Technologies had a net margin of 9.96% and a return on equity of 20.45%. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.07 earnings per share. Equities analysts anticipate that GE HealthCare Technologies will post 5.02 EPS for the current fiscal year.

Institutional Trading of GE HealthCare Technologies

Several hedge funds have recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC grew its position in GE HealthCare Technologies by 1.9% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 7,246 shares of the company’s stock worth $518,000 after purchasing an additional 133 shares in the last quarter. Mount Vernon Associates Inc. MD raised its position in GE HealthCare Technologies by 0.8% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 18,165 shares of the company’s stock worth $1,293,000 after buying an additional 144 shares during the last quarter. Carnegie Investment Counsel raised its holdings in shares of GE HealthCare Technologies by 2.0% during the 3rd quarter. Carnegie Investment Counsel now owns 7,678 shares of the company’s stock valued at $502,000 after buying an additional 151 shares during the period. Essex Financial Services Inc. lifted its holdings in GE HealthCare Technologies by 1.8% in the 1st quarter. Essex Financial Services Inc. now owns 9,024 shares of the company’s stock valued at $642,000 after acquiring an additional 156 shares during the last quarter. Finally, Beacon Financial Advisory LLC lifted its stake in shares of GE HealthCare Technologies by 5.8% in the first quarter. Beacon Financial Advisory LLC now owns 2,965 shares of the company’s stock valued at $211,000 after buying an additional 162 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Strong Q3 results beat expectations. GE HealthCare reported $5.51 billion in revenue, above the $5.35 billion consensus estimate, while EPS of $1.34 exceeded expectations of $1.20. Revenue increased 7.2% year over year, helping drive the post-earnings gap higher. GE HealthCare Technologies Shares Gap Up After Strong Earnings
• Positive Sentiment: Management raised its full-year outlook. The company now expects approximately 4% organic revenue growth, adjusted EPS of $4.95–$5.05, and at least $1.6 billion in free cash flow. Organic growth of 6.2% and margin expansion in the quarter further strengthened the bullish case. GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling
• Positive Sentiment: Analysts raised valuation targets. RBC increased its target from $80 to $90 and maintained an “outperform” rating. BNP Paribas lifted its target from $96 to $100, while Mizuho raised its target from $85 to $90. BTIG Research also forecast substantial potential appreciation. BNP Paribas Price Target Update
• Neutral Sentiment: JPMorgan raised its price target from $70 to $80 but kept a “neutral” rating, suggesting recognition of the earnings improvement while retaining a cautious stance on valuation. JPMorgan GE HealthCare Rating
• Neutral Sentiment: A value comparison with Haemonetics highlights GEHC’s investment appeal but does not introduce a material new catalyst for the stock. GEHC Versus HAE Value Comparison

About GE HealthCare Technologies

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company’s portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.